Market revenue in 2023 | USD 156.8 million |
Market revenue in 2030 | USD 215.8 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.71% in 2023. Horizon Databook has segmented the Saudi Arabia rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The Saudi Arabia rheumatoid arthritis therapeutics market has seen key developments, particularly with the approval of new biosimilar drugs. In January 2023, a significant milestone was achieved with the approval of AVT02, a biosimilar for Humira (adalimumab), by the Saudi Food & Drug Authority (SFDA).
This approval came as part of a strategic partnership between Alvotech and Bioventure, marking the first biosimilar to be approved under this collaboration. AVT02, which will be marketed as Simlandi in Saudi Arabia, offers a more cost-effective alternative to Humira and is indicated for the treatment of RA and several other inflammatory diseases.
This approval reflects the growing interest and investment in biosimilars to enhance healthcare access and affordability in the country. Biosimilars such as Simlandi have the potential to expand treatment options for RA patients, providing them with more choices and potentially improving treatment outcomes.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account